Novartis to invest $1B in R&D in China, buy vaccine firm
Novartis plans to invest $1 billion in the next five years in research and development in China to take advantage of planned health care reform in the country. The Swiss drugmaker also is buying an 85% stake in Zhejiang Tianyuan Bio-Pharmaceutical, a vaccine company, for $125 million.
Reuters | 11/04
This story published in BIO SmartBrief on 11/04/2009
More from SmartBrief:
PPD to take over China's BioDuro
Friday, November 20, 2009
Health care firms raised $2.23B in venture funding in Q2
Monday, July 20, 2009
States accuse Amgen of kickbacks to boost Aranesp sales
Monday, November 2, 2009
Get stories like these delivered daily for FREE:
|
BIO SmartBrief
Designed specifically for biotechnology industry professionals like you, BIO SmartBrief is a FREE daily e-mail newsletter. It provides the latest news and information you need to stay informed about important biotech issues. Learn more |
|